Targeted treatment and new agents in peripheral T-cell lymphoma (Q37763879)

22 August 2017

1 reference

title

Targeted treatment and new agents in peripheral T-cell lymphoma (English)

1 reference

22 August 2017

Jasmine M Zain

1

1 reference

PubMed ID

20535594

22 August 2017

Owen O'Connor

series ordinal

2

1 reference

22 August 2017

10 June 2010

1 reference

International Journal of Hematology

22 August 2017

1 reference

22 August 2017

92

1 reference

22 August 2017

1

1 reference

22 August 2017

33-44

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-010-0614-9

22 August 2017

0 references

cites work

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

1 reference

12 December 2020

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

1 reference

12 December 2020

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

1 reference

12 December 2020

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

12 December 2020

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

1 reference

12 December 2020

A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice

1 reference

12 December 2020

Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

12 December 2020

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

12 December 2020

New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties

1 reference

12 December 2020

Epigenetic modifiers: basic understanding and clinical development.

1 reference

12 December 2020

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

1 reference

12 December 2020

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

12 December 2020

WHO-EORTC classification for cutaneous lymphomas

1 reference

12 December 2020

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers

1 reference

12 December 2020

P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma.

1 reference

12 December 2020

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

12 December 2020

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

12 December 2020

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

12 December 2020

Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin

1 reference

12 December 2020

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides

1 reference

12 December 2020

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

12 December 2020

The Bcl-2 family: roles in cell survival and oncogenesis.

1 reference

12 December 2020

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

1 reference

12 December 2020

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

12 December 2020

A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

1 reference

12 December 2020

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

1 reference

12 December 2020

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

1 reference

12 December 2020

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

1 reference

12 December 2020

Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression

1 reference

12 December 2020

Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.

1 reference

12 December 2020

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

12 December 2020

The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis

1 reference

12 December 2020

Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant

1 reference

12 December 2020

Mechanisms of HDAC inhibitor-induced thrombocytopenia

1 reference

12 December 2020

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

1 reference

12 December 2020

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

12 December 2020

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

12 December 2020

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

1 reference

12 December 2020

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

1 reference

12 December 2020

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

12 December 2020

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

1 reference

12 December 2020

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

1 reference

12 December 2020

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

12 December 2020

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

1 reference

12 December 2020

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

1 reference

12 December 2020

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

1 reference

12 December 2020

All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

Bortezomib: proteasome inhibition as an effective anticancer therapy

1 reference

12 December 2020

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

12 December 2020

Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).

1 reference

12 December 2020

The development of proteasome inhibitors as anticancer drugs

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

1 reference

12 December 2020

Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)

1 reference

12 December 2020

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

1 reference

12 December 2020

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

1 reference

12 December 2020

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

1 reference

12 December 2020

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

1 reference

12 December 2020

10.1007/S12185-010-0614-9

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20535594